'Ruxolitinib' presentation slideshows

JAK inhibitors update from ASH

433 views • 42 slides

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine

ASH 2012: New JAK Inhibitors for Myelofibrosis. Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine. Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA.

431 views • 30 slides

Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine

ASH 2012: New JAK Inhibitors for Myelofibrosis. Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine. Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA.

410 views • 30 slides

Update on Alopecia Areata Research

254 views • 21 slides

1 Verstovsek S et al. Proc ASH 2012;Abstract 800. 2 Cervantes F et al.

340 views • 18 slides

Verstovsek S et al. Proc ASH 2011;Abstract 278.

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results from COMFORT-I. Verstovsek S et al. Proc ASH 2011;Abstract 278. Background.

286 views • 9 slides

Verstovsek S et al. Proc ASH 2011;Abstract 793.

Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy. Verstovsek S et al. Proc ASH 2011;Abstract 793. Background.

239 views • 9 slides

Jakavi 5mg(Ruxolitinib)-Uses, Side Effects, Substitutes, Composition And More|Apple Pharmaceuticals

Jakavi 5mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production

67 views • 6 slides

Jakavi 10mg(Ruxolitinib)-Uses,Side Effects,Substitutes,Composition And More|Apple Pharmaceuticals

Jakavi 10mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production.

68 views • 6 slides

Jakavi 15mg(Ruxolitinib)-Uses,Side Effects,Substitutes,Composition And More|Apple Pharmaceuticals

Jakavi 15mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production .

66 views • 6 slides

Jakavi 20mg(Ruxolitinib)-Uses,Side Effects,Substitutes,Composition And More|Apple Pharmaceuticals

Jakavi 20mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production @ Apple pharmaceuticals

67 views • 6 slides

Jakavi 25mg(Ruxolitinib)-Uses,Side Effects,Substitutes,Composition And More|Apple Pharmaceuticals

Jakavi 25mg belongs to the type of targeted therapy. It is an oral receptor tyrosine kinase inhibitor. It acts by inhibiting certain enzymes in the body which affect blood cell production.

73 views • 6 slides